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Introduction: Premature infants face multiple challenges including periventricular leuko-
malacia (PVL) and successful therapies are lacking. Neural stem cells (NSCs) from the sub-
ventricular zone give rise to myelin producing cells during brain development. Post-injury, 
activation of dormant NSCs represents an attractive strategy and long non-coding RNA H19 
is a potential candidate to regulate cell differentiation. Since synthetic PreImplantation fac-
tor (sPIF) protects against multiple neuronal disorders, we posit that sPIF activates NSCs af-
ter injury by modulating H19 and therefore modulates myelin.
Methods: Cell lines (Immature oligodendrocytes MO13.13) were treated with sPIF (200nM; 
48h), and evaluated by quantitative RT-PCR and H19 silencing was performed. We used a 
mouse model of PVL (LPS and hypoxia-ischemia; n=20) to test specific effects on NSCs. All ani-
mals were electroporated with a pCAG-Cre plasmid to permanently label NSCs at P0. Injury 
group was subjected to brain injury and received NaCl as treatment; Sham animals served 
as healthy controls. sPIF (0.75 mg/kg sc twice daily) treatment was started from P0 until P7. 
As a proof of concept we used a constitutively active plasmid encoding H19 (pCMV-H19CA) 
to increase H19 activity in NSCs. We evaluated animals by MRI, immunohistochemistry, and 
in-situ hybridization at P7 with special focus on labeled NSCs. Two-tailed Student’s t-test and 
Mann- Whitney tests were used in analysis with level of significance set at p <0.05.
Results: We detected myelin loss by reduced fractional anisotropy (FA), diffusion tensor 
imaging and myelin basic proteins (MBP) intensity post- injury. Both sPIF and H19CA ame-
liorated this loss significantly, increasing both FA and MBP intensity. Furthermore, sPIF and 
H19CA resulted in increased NSCs differentiation. In cell lines, sPIF increased mRNA expres-
sion of immature (OLIG2) and mature (MBP) oligodendrocyte markers in H19-dependent 
manner. sPIF also increased H19 expression in the brain, as detected by in-situ hybridization. 
Conclusion: sPIF activates NSCs and prevents myelin loss after injury by modulating H19 of 
the NSCs. Given the FDA Fast Track designation and safety data of sPIF in First in Human Cli-
nical Trial (ClinicalTrials.gov Identifier: NCT02239562), clinical trials to prevent or treat PVL 
can be envisioned.
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